Literature DB >> 19261399

Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants.

U Antia1, H S Lee, R R Kydd, M D Tingle, B R Russell.   

Abstract

There have been many reports of benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) being used as recreational drugs which have been widely marketed in the form of 'party pills' since the late 1990's. However, there is no information currently available describing the pharmacokinetics of these drugs in humans. Human plasma concentrations of BZP were measured in blood and urine samples taken from healthy adults (n=7) over 24h following a 200mg oral dose of BZP. Plasma concentrations of BZP were found to peak at 262 ng/mL (C(max)) and 75min (T(max)). Plasma concentrations of the major metabolites of BZP, 4-OH BZP and 3-OH BZP, were found to peak at 7 ng/mL (at 60 min) and 13 ng/mL (at 75 min) respectively. The elimination half-life (t(1/2)) for BZP was found to be 5.5h. Clearance (Cl/F) was found to be 99L/h. The results of this study indicate that BZP may be detectable in plasma for up to 30 h following an oral dose. Additionally, several urinary metabolites can be detected.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261399     DOI: 10.1016/j.forsciint.2009.01.015

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  5 in total

1.  Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.

Authors:  Louise E Curley; Rob R Kydd; Michelle C Robertson; Avinesh Pillai; Nicolas McNair; HeeSeung Lee; Ian J Kirk; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2015-04-19       Impact factor: 4.530

2.  Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.

Authors:  Tibor M Brunt; Maarten W Koeter; Raymond J M Niesink; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2011-10-13       Impact factor: 4.530

3.  Determining the subjective and physiological effects of BZP combined with TFMPP in human males.

Authors:  Joanne C Lin; Reem K Jan; HeeSeung Lee; Maree-Ann Jensen; Rob R Kydd; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2011-04       Impact factor: 4.530

4.  An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse.

Authors:  Karolina Persona; Anna Polus; Joanna Góralska; Anna Gruca; Aldona Dembińska-Kieć; Wojciech Piekoszewski
Journal:  Neurotox Res       Date:  2016-02-09       Impact factor: 3.911

Review 5.  An Update on the Implications of New Psychoactive Substances in Public Health.

Authors:  Ana Y Simão; Mónica Antunes; Emanuel Cabral; Patrik Oliveira; Luana M Rosendo; Ana Teresa Brinca; Estefânia Alves; Hernâni Marques; Tiago Rosado; Luís A Passarinha; Maristela Andraus; Mário Barroso; Eugenia Gallardo
Journal:  Int J Environ Res Public Health       Date:  2022-04-17       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.